COVID-19 Impact on EU MDR: UPDATE

by | Apr 20, 2020 | Coronavirus, COVID-19, EU, EU MDR, FDA, Medical Devices, Quality Systems, Requirements

In our last blog on COVID-19’s impact on the EU MDR, the commission had not yet laid out any intentions of moving the EU MDR deadline, which was slated for next month. With close to 2 million confirmed cases globally, it seems that the pandemic’s impact has finally forced the commission to postpone the deadline for the EU MDR.1 On April 3rd, the commission officially adopted a proposal to postpone the deadline by one year, meaning medical device manufacturers now have until May 26, 2021 to transition to the new regulation.

According to the Commission, the decision was not reached lightly. The transition deadline that was set for next month was something medical device manufacturers have worked tirelessly towards since the EU MDR was announced; however, the obvious need to prioritize the fight against COVID-19 has forced the postponement. It was recognized that the relaxation of the deadline would ensure that medical device firms could effectively address the worldwide shortage of critical medical devices. The coronavirus pandemic presents unprecedented challenges to all medical device manufacturers, and the commission recognized that postponing the deadline would allow firms to allocate the proper resources to the current public health emergency.

The Vice President for Promoting our European Way of Life, Margaritis Schinas, said “Shortages or delays in getting key medical devices certified and on the market are not an option right now. The Commission is, therefore, taking a pragmatic approach and delaying the entry into application of new EU rules on medical devices, so we can have our medical industries pouring all their energy into what we need them to be doing: helping fight the pandemic.”2 The current EU directives for medical devices (including implantable devices) will stay in regulation until the new 2021 EU MDR date. The date for the IVDR, however, is still on target for May 26, 2022.

EMMA International is keeping up to date with all regulatory responses to the COVID-19 pandemic; give us a call at 248-987-4497 or email info@emmainternational.com for more information!


1WHO (April 2020) Coronavirus Disease 2019 (COVID-19) Situation Report 85 retrieved on 04/15/2020 from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200415-sitrep-86-covid-19.pdf?sfvrsn=c615ea20_4

2European Commission (April 2020) Commission postpones application of the medical devices regulation to prioritize the fight against coronavirus retrieved on 04/14/2020 from: https://ec.europa.eu/commission/presscorner/detail/en/ip_20_589

Madison Wheeler

Madison Wheeler

Director of Technical Operations - Ms. Wheeler serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Ms. Wheeler also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Ms. Wheeler holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This